Compare Ascendis Pharma A/S (ASND) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Peloton Interactive Inc — how do they compare? Ascendis Pharma A/S trades at $256.59 (market cap $16.67B), while Peloton Interactive Inc trades at $5.46 (market cap $2.46B). The key difference: Ascendis Pharma A/S is far larger — about 6.8× Peloton Interactive Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PTON | |
|---|---|---|
Market Cap | $16.67B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $9.00 |
52-Week Low | $189.74 | $3.71 |
Enterprise Value | $17.04B | $2.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Peloton Interactive (PTON) trades at $5.45, down 1.09% on the day, reflecting ongoing investor caution despite achieving its first full-year net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals highlight a challenging revenue decline to $2.4B in 2026, though net income turned positive at $63M. Analyst sentiment is mixed, with a 'Hold' consensus amid concerns over subscriber losses and a muted 2027 outlook.
The outlook remains cautious; profitability improvements and cost control offer a foundation, but persistent revenue declines and high debt levels pose significant risks. Investors should weigh the company's turnaround progress against competitive pressures and execution challenges in a saturated fitness market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
